We then correlated SLFN11 expression with clinicopathological features of CRC, including primary tumor location, tumor differentiation, preoperative Cancinoembryonic Antigen(CEA) level, TNM staging, KRAS exon 2 status, age and sex. This evidence concerns the gene KRAS and colorectal carcinoma.